Cargando…

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines

Detalles Bibliográficos
Autores principales:	Cavaleri, Marco, Enzmann, Harald, Straus, Sabine, Cooke, Emer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833511/ https://www.ncbi.nlm.nih.gov/pubmed/33453149 http://dx.doi.org/10.1016/S0140-6736(21)00085-4

Ejemplares similares

Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
por: Jaeger, Simon U, et al.
Publicado: (2022)

Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
por: Collignon, Olivier, et al.
Publicado: (2018)

Emergency use authorisation for COVID-19 vaccines: lessons from Ebola
por: Smith, Maxwell J, et al.
Publicado: (2020)

The European Space Agency’s Comet Interceptor lies in wait
por: Snodgrass, Colin, et al.
Publicado: (2019)

Preparing Europe for future health threats and crises ─ the European Medicines Agency; ensuring safe and effective medicines and medical devices
por: Cooke, Emer
Publicado: (2022)

The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
por: Ghalandari, N., et al.
Publicado: (2020)

Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021
por: Essink, Sharon C. M., et al.
Publicado: (2023)

EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
por: Detela, Giulia, et al.
Publicado: (2019)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency
por: Pelfrene, Eric, et al.
Publicado: (2015)

The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis
por: Pelfrene, Eric, et al.
Publicado: (2019)

Stakeholders’ Understanding of European Medicine Agency’s COVID-19 Vaccine Information Materials in EU and Regional Contexts
por: Castro, Indiana, et al.
Publicado: (2023)

The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children
por: Kreeftmeijer-Vegter, Annemarie Rosan, et al.
Publicado: (2014)

Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union
por: Hoeve, Christina E., et al.
Publicado: (2019)

Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2021)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

Foods, Nutrients and Food Ingredients with Authorised EU Health Claims
por: Sadler, Michele
Publicado: (2014)

Comment on Fauconnier, A. Phage Therapy Regulation: From Night to Dawn
por: Pelfrene, Eric, et al.
Publicado: (2019)

Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012
por: Lane, Samantha, et al.
Publicado: (2018)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

Shaping EU medicines regulation in the post COVID-19 era
por: Cavaleri, Marco, et al.
Publicado: (2021)

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
por: Michaleas, S., et al.
Publicado: (2022)

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018
por: Schuster Bruce, Catherine, et al.
Publicado: (2019)

Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation
por: Vatzaki, Efstratia, et al.
Publicado: (2018)

Building organizational reputation in the European regulatory state: An analysis of EU agencies' communications
por: Rimkutė, Dovilė
Publicado: (2019)

Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2022)

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study
por: Xie, Jinping, et al.
Publicado: (2023)

Real‐World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value
por: Arlett, Peter, et al.
Publicado: (2021)

Plans for EU disease control centre given boost
Publicado: (2013)

Plans for EU disease control centre given boost
Publicado: (2013)

Values in challenging times: strategic crisis management in the EU
por: Prainsack, Barbara, et al.
Publicado: (2022)

COVID-19 vaccines for the European region: an unprecedented challenge
por: Kluge, Hans, et al.
Publicado: (2021)

PReS13-SPK-1408: New EU scientific guidelines for JIA, SLE and GIOP from the European Medicines Agency
por: Vesely, R
Publicado: (2013)

Impact of Amending the Acetylcysteine Marketing Authorisation on Treatment of Paracetamol Overdose
por: Thompson, G., et al.
Publicado: (2013)

Severe mental illness and European COVID-19 vaccination strategies
por: De Picker, Livia J, et al.
Publicado: (2021)

Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder
por: Agyemang, Elaine, et al.
Publicado: (2017)

Comparison among Certain Antiseptics and the Agencies
Publicado: (1918)

Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
por: Elsäßer, Amelie, et al.
Publicado: (2014)

An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register
por: Carroll, Robert, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o491ktc38998igb68i12q32nup